Renan Augusto Gomes

Renan Augusto Gomes

Auto-generated profile, based on publicly available information

Renan Augusto Gomes

School of Pharmaceutical Sciences University of São Paulo Av. Lineu Prestes 580 Cidade Universitária São Paulo SP 05508-000 Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in Future Medicinal Chemistry
Verified
Journal Article
Open access
WFWitor Ribeiro Ferraz
Witor Ribeiro Ferraz
RGRenan Augusto Gomes
Renan Augusto Gomes
ANAndre Luis S Novaes
Andre Luis S Novaes
GTGustavo Trossini
Gustavo Trossini
Aim: The identification of drugs for the coronavirus disease-19 pandemic remains urgent. In this manner, drug repurposing is a suitable strategy, saving resources and time normally spent during reg... Graphical abstract

1 February 2023 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
APAndré Berndt Penteado
André Berndt Penteado
HHHaifa Hassanie
Haifa Hassanie
RGRenan Augusto Gomes
Renan Augusto Gomes
FEFlavio Emery
Flavio Emery
GTGustavo Trossini
Gustavo Trossini
The silent information regulator (sirtuin) is a family of enzymes involved in epigenetic processes with lysine deacetylase activity, having as substrates histones and other proteins. They participa...

7 June 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
CHCintia Scucuglia Heluany
Cintia Scucuglia Heluany
PDPaula Barbim Donate
Paula Barbim Donate
ASAyda Henriques Schneider
Ayda Henriques Schneider
AFAndré Luis Fabris
André Luis Fabris
RGRenan Augusto Gomes
Renan Augusto Gomes
SFSandra H.P. Farsky
Sandra H.P. Farsky
Rheumatoid arthritis (RA) development is strongly associated with cigarette smoke exposure, which activates the aryl hydrocarbon receptor (AhR) as a trigger for Th17 inflammatory pathways. We previously demonstrated that the exposure to hydroquinone (HQ), one of the major compounds of cigarette tar, aggravates the arthritis symptomatology in rats. However, the mechanisms related to the HQ-related RA still remain elusive. Cell viability, cytokine secretion, and gene expression were measured in RA human fibroblast-like synoviocytes (RAHFLS) treated with HQ and stimulated or not with TNF-α. Antigen-induced arthritis (AIA) was also elicited in wild type (WT), AhR −/− or IL-17R −/− C57BL/6 mice upon daily exposure to nebulized HQ (25ppm) between days 15 to 21. At day 21, mice were challenged with mBSA and inflammatory parameters were assessed. The in vitro HQ treatment up-regulated TNFR1, TNFR2 expression, and increased ROS production. The co-treatment of HQ and TNF-α enhanced the IL-6 and IL-8 secretion. However, the pre-incubation of RAHFLS with an AhR antagonist inhibited the HQ-mediated cell proliferation and gene expression profile. About the in vivo approach, the HQ exposure worsened the AIA symptoms (edema, pain, cytokines secretion and NETs formation) in WT mice. These AIA effects were abolished in HQ-exposed AhR −/− and IL-17R −/− animals though. Our data demonstrated the harmful HQ influence over the onset of arthritis through the activation and proliferation of synoviocytes. The HQ-related RA severity was also associated with the activation of AhR and IL-17 pathways, highlighting how cigarette smoke compounds can contribute to the RA progression.

23 November 2021 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ELElys Juliane Cardoso Lima
Elys Juliane Cardoso Lima
RGRenan Augusto Gomes
Renan Augusto Gomes
EFEvelin Fornari
Evelin Fornari
FEFlavio Emery
Flavio Emery
GTGustavo Trossini
Gustavo Trossini
The development of new drugs is becoming notably harder each decade. To overcome the present pitfalls in the drug development pipeline, such as those related to potency, selectivity, or absorption, distribution, metabolism, excretion and toxicity properties, medicinal chemistry strategies need to be in continuous evolution and need to become even more multidisciplinary. In this review, we present how structure-based, ligand-based, and fragment-based drug design (SBDD, LBDD, and FBDD, respectively) and their respective techniques were used for the design and optimization of successful cases of New Molecular Entities (NMEs) approved by the Food and Drug Administration (FDA).

30 June 2021 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
RGRenan Augusto Gomes
Renan Augusto Gomes
EFEvelin Fornari
Evelin Fornari
ARAna Carolina Silva Rocha
Ana Carolina Silva Rocha
GTGustavo Luis Tripodi
Gustavo Luis Tripodi
FEFlavio Emery
Flavio Emery
GTGustavo Trossini
Gustavo Trossini
Infections caused by protozoans remain a public health issue, especially in tropical countries. Serious adverse events, lack of efficacy at the different stages of the infection and routes of admin...